Regional Monitoring EECA
by ECUO PLWH
Regional Monitoring EECA
Showing 1-4 of 4 items.
| # | Country | Source of financing | Manufacturer | Tradename | INN | Form | Price per unit ($) | Units in purchase | Units in package | Price per package ($) | Packages in purchase | Price per purchase ($) | Distributor | Year | Purchase date | Delivery date | Registered | In the list of main (vital) medications | WHO prequalification |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Republic of Poland | Government | AbbVie | Kaletra | Lopinavir+Ritonavir - FDC | 80mg/ml+20mg/ml oral solution 100ml | 295.52 | 20 | 1 | 295.52 | 20 | 5910.4 | Krajowe Centrum ds. AIDS | 2016 | Yes | Yes | Not specified | ||
| 2 | Republic of Poland | Government | AbbVie | Kaletra | Lopinavir+Ritonavir - FDC | 80mg/ml+20mg/ml oral solution 100ml | 59.104 | 150 | 5 | 295.52 | 30 | 8865.6 | Krajowe Centrum ds. AIDS | 2016 | Not specified | Not specified | Not specified | ||
| 3 | Kyrgyz Republic | Global Fund | AbbVie | Kaletra | Lopinavir+Ritonavir - FDC | 80mg/ml+20mg/ml oral solution 100ml | 12.16 | - | 5 | 60.8 | - | - | UNDP/UNICEF | 2015 | 2014-12-31 | 2015-12-30 | Not specified | Not specified | Not specified |
| 4 | Republic of Tajikistan | Global Fund | Aurobindo Pharma Ltd. | Lopinavir+Ritonavir - FDC | 80mg/ml+20mg/ml oral solution 100ml | 12.2 | 504 | 1 | 12.2 | 504 | 6148.8 | UNDP/UNICEF | Not specified | Not specified | Not specified |